Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O15118

UPID:
NPC1_HUMAN

ALTERNATIVE NAMES:
Niemann-Pick C1 protein

ALTERNATIVE UPACC:
O15118; B4DET3; Q9P130

BACKGROUND:
The Niemann-Pick C1 protein, essential for intracellular cholesterol transport, is implicated in maintaining lipid homeostasis by facilitating cholesterol movement out of lysosomes. Its interaction with NPC2 and high affinity for oxysterol suggest a complex role in cellular lipid management and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the pathogenesis of Niemann-Pick disease C1, a disorder characterized by disrupted lipid storage, the NPC1 protein represents a promising target for therapeutic intervention. Advances in understanding its function could lead to novel treatments for this debilitating disease, offering hope for patients and families.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.